AFT Pharmaceuticals SA acquires the Hospital Division of Pharma Dynamics

AFT Pharmaceuticals SA (Pty) Ltd (‘AFT SA’) announces it has successfully completed the acquisition of the Hospital Division business of Pharma Dynamics (Pty) Ltd (‘Pharma Dynamics’).

AFT SA is a subsidiary of AFT Pharmaceuticals Limited (“AFT Pharmaceuticals), a multinational pharmaceutical company listed on the New Zealand Stock Exchange (NZX) and Australian Stock Exchange (ASX).

Since its inception in 1998, AFT Pharmaceuticals has built a proven track record for the development, manufacture and licensing of a wide range of over-the-counter, prescription and hospital medicines, now available more than 85 countries worldwide.

Established in South Africa 11 months ago, AFT SA’s strategy has initially focused on hospital-based medicines.

“As an organisation committed to high-quality products and exceptional customer support, this acquisition is an ideal fit,’ says AFT SA Chief Executive Deon Hall. “Pharma Dynamics’ strong portfolio will help us to build market presence in hospitals and continue its legacy.”

The transaction was completed on 28 November 2025, with a phased transition plan underway since early October to maintain operations and stock supply.

“Both companies are committed to a smooth handover, and we are working closely together to ensure this occurs. We also look forward to building strong, enduring relationships with our customers and partners,” says Hall.

Click here for further information about AFT SA, its team and products. A list of the products acquired from Pharma Dynamics is provided on the next page.

Ends

 

For further information:

Deon Hall

Chief Executive Officer

AFT SA

 

Email : deon.hall@aftpharm.com

Mobile : +27 832268475

 

AFT SA has acquired the following hospital-based medicines as part of the transaction:

 

Brand SKU Molecule Description
Altirem 1mg, 2mg, 5mg remifentanil Analgesic
Cusyn 500mg daptomycin Antimicrobial or anti-infectives
Cytagil 50mg tigecycline Antimicrobial or anti-infectives
Emistop 4mg, 8mg ondansetron Anti-emetics
Invabex 1g ertapenem Antimicrobial or anti-infectives
Ivecas 50mg, 70mg caspofungin Antifungals
Klotigo 500mg/5ml tranexamic acid Blood clotting products
Myceno 50mg, 100mg micafungin Antifungals
Meroject 500mg, 1g meropenem anhydrous Antimicrobial or anti-infectives
Sepencil 500mg imipenem/cilastatin Antimicrobial or anti-infectives
Teicoplanin 200mg, 400mg teicoplanin Antimicrobial or anti-infectives
Trakeze 50mg/5ml rocuronium bromide Anaesthetic muscle relaxant
Truloc IV 40mg esomeprazole Gastro-intestinal tract products
Velpalex 400mg IV sodium valproate Anticonvulsants and anti-epileptics
Vondip 200mg voriconazole Antifungals

 

 

November 12, 2025

AFT Pharmaceuticals Brings Next-Generation Liposomal Collagen and Wellness Range to the U.S. Market 

AFT Pharmaceuticals has launched its full Lipo-Sachets® range in the U.S., featuring advanced collagen and vitamin supplements powered by patented LI…

Read More

May 26, 2025

AFT and Hikma extend US Maxigesic Cooperation

AFT Pharmaceuticals (NZX:AFT, ASX:AFP) today announces it has extended its US Maxigesic® licensing agreement with Hikma Pharmaceuticals….

Read More

May 1, 2024

AFT Licenses Maxigesic® IV in Brazil

We are delighted to announce our partnership with Brazil’s Halex Istar, and to be exclusively responsible for distributing its Maxigesic IV in Brazi…

Read More